Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
The main practical difference is that Wegovy comes in higher doses and uses auto-injector pens, while Ozempic uses injection pens with dose selectors
2021;31(2):e0051921
2, 2016 Too many cavaliers are too fat
Not merely an anesthetic, Ketamine's complex interaction with neurons could potentially revolutionize therapies for mental health conditions
For many, the frustration of stalled progress or the inability to access high-demand medications has led to questions about alternative options